SUNEENA POKKAMTHANAM: Open Payments
NPI 1396163945 · BAKERSFIELD, CA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$830 in 43 payments from 12 companies in 2025. Trend: 2023 $274 · 2024 $955 · 2025 $830
Food & beverage: $830
| Company | Payments | Amount |
|---|---|---|
| Teva Pharmaceuticals USA, Inc. | 14 | $237 |
| Alkermes, Inc. | 5 | $111 |
| Supernus Pharmaceuticals, Inc. | 5 | $90 |
| Otsuka America Pharmaceutical, Inc. | 4 | $87 |
| Lundbeck LLC | 4 | $87 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 2 | $52 |
| Neurocrine BioSciences, Inc. | 2 | $48 |
| Janssen Pharmaceuticals, Inc | 2 | $38 |
| E.R. Squibb & Sons, L.L.C. | 2 | $30 |
| Axsome Therapeutics, Inc. | 1 | $22 |
Products named: AUSTEDO XR, ARISTADA, REXULTI, Qelbree, ABILIFY ASIMTUFII, CAPLYTA, INGREZZA, INVEGA SUSTENNA.
Industry payments across CA — which companies pay providers there.
